The Effects of Telmisartan on High Sensitivity CRP and Cys C in Patients with Early Diabetic Nephropathy
FENG Qiong,RAN Jian-min,LAO Gan-cheng,WANG Hui,ZHANG Yang,LIU Wei
DOI: https://doi.org/10.3969/j.issn.1008-1836.2008.01.008
2008-01-01
Abstract:Objective: To evaluate the effects of Telmisartan on the levels of high sensitivity C-reactive protein (hsCRP) and serum cystatin C (Cys C) in patients with early diabetic nephropathy (DN). Methods: Eighty-five patients with early DN were randomly assigned to the control group (n=40) treated on nitrendipine or the intervention group (n=45) treated on telmisartan, while receiving concomitant regular insulin, for 12 weeks. Changes before and after treatment in levels of blood pressure, serum lipids, plasma glucose, HbA1c, urine albumin excretion rate (UAER), hsCRP and Cys C were observed and compared between the two groups. Results:The two groups showed similar levels of the indexes at baseline (P>0.05). After 12 weeks of treatment, UAER, serum TC, TG, HDL-C, LDL-C, fasting blood sugar, 2 h postprandial blood sugar, HbA1c, hsCRP, Cys C and blood pressure were significantly improved in both groups (P<0.01). The intervention group showed greater improvement in UAER, TC, HDL-C, LDL-C, hsCRP and Cys C (P<0.05 or P<0.01) compared with the controls. Conclusion: Use of telmisartan in the treatment of early diabetic nephropathy can decrease the levels of hsCRP, Cys C and microalbuminuria, and may show promises for delaying the progression of early diabetic nephropathy.